ALOFISEL

This brand name is authorized in Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Lithuania, Poland, Romania, United Kingdom

Active ingredients

The drug ALOFISEL contains one active pharmaceutical ingredient (API):

1 Darvadstrocel UNII 31W7R94KYT - DARVADSTROCEL

Darvadstrocel contains expanded adipose stem cells (eASC), which exhibit immunomodulatory and anti-inflammatory effects at inflammation sites. Read about Darvadstrocel

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ALOFISEL Suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04	Immunosuppressants	L Antineoplastic and immunomodulating agents
Discover more medicines within L04
L04AX08		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AX Other immunosuppressants
Discover more medicines within L04AX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1768226
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1171261001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 480329
Country: FR	Base de données publique des médicaments	Identifier(s): 60511177
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 368875
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8482
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1085323
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100403918
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64494001